Fresenius SE & Co KGaA
XETRA:FRE

Watchlist Manager
Fresenius SE & Co KGaA Logo
Fresenius SE & Co KGaA
XETRA:FRE
Watchlist
Price: 33.31 EUR 1.59% Market Closed
Market Cap: 18.8B EUR
Have any thoughts about
Fresenius SE & Co KGaA?
Write Note

Fresenius SE & Co KGaA
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Fresenius SE & Co KGaA
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Fresenius SE & Co KGaA
XETRA:FRE
Pre-Tax Income
€935m
CAGR 3-Years
-36%
CAGR 5-Years
-25%
CAGR 10-Years
-9%
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
Pre-Tax Income
€1.1B
CAGR 3-Years
-14%
CAGR 5-Years
-10%
CAGR 10-Years
-2%
Vita 34 AG
XETRA:V3V
Pre-Tax Income
-€2.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
E
Euroeyes International Eye Clinic Ltd
HKEX:1846
Pre-Tax Income
HK$190.6m
CAGR 3-Years
25%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Synlab AG
XETRA:SYAB
Pre-Tax Income
€143m
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Fresenius Medical Care AG
XMUN:FME
Pre-Tax Income
€1.1B
CAGR 3-Years
-14%
CAGR 5-Years
-10%
CAGR 10-Years
-2%
No Stocks Found

Fresenius SE & Co KGaA
Glance View

Market Cap
18.8B EUR
Industry
Health Care

Fresenius SE & Co KGaA is a global healthcare group rooted in Germany, dedicated to providing high-quality medical services and products to patients worldwide. Founded in 1912, the company has grown into a diverse organization with a strong focus on life-saving therapies in renal care, hospital services, and pharmaceutical manufacturing. With its subgroups—Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed—the company operates across different segments that collectively support its vision of enhancing patient outcomes, improving quality of care, and meeting the increasing demand for healthcare services in an aging global population. By leveraging an extensive network of healthcare facilities, innovative product pipelines, and a commitment to sustainability, Fresenius positions itself as a leader in the dynamic healthcare landscape. For investors, Fresenius SE & Co KGaA represents an opportunity to engage with a stable yet growth-oriented enterprise. The company has consistently demonstrated resilience, even amidst market fluctuations, reflecting a strong financial foundation and strategic leadership. With the global healthcare market projected to expand, driven by an increase in chronic diseases and the need for advanced medical solutions, Fresenius is well-poised to capture significant market share. Its focus on innovation, particularly in personalized medicine and digital health, underscores a forward-thinking approach that aligns with evolving patient needs. As a long-term investment option, Fresenius' commitment to enhancing healthcare accessibility and efficiency not only offers the potential for financial returns but also contributes positively to global health outcomes, making it a compelling choice for investors looking for a balance of impact and profit.

FRE Intrinsic Value
70.19 EUR
Undervaluation 53%
Intrinsic Value
Price

See Also

What is Fresenius SE & Co KGaA's Pre-Tax Income?
Pre-Tax Income
935m EUR

Based on the financial report for Sep 30, 2024, Fresenius SE & Co KGaA's Pre-Tax Income amounts to 935m EUR.

What is Fresenius SE & Co KGaA's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-9%

Over the last year, the Pre-Tax Income growth was -52%. The average annual Pre-Tax Income growth rates for Fresenius SE & Co KGaA have been -36% over the past three years , -25% over the past five years , and -9% over the past ten years .

Back to Top